When Science Meets Real-World Struggle

Every year, the promise of new therapies often stalls because of one often-overlooked factor: it’s too hard for people to participate. Protocol complexity is rising. Study visits are long, logistics are daunting, but development teams feel stuck with these obstacles. “Maybe it won’t be too bad?”

Participation burden isn’t theoretical. It’s quantifiable, impactful, and—most importantly—preventable.